Journey Medical (NASDAQ:DERM) Lowered to Hold Rating by Wall Street Zen

Journey Medical (NASDAQ:DERM - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Sunday.

Several other equities analysts have also recently issued reports on DERM. Industrial Alliance Securities set a $10.50 price objective on Journey Medical in a research report on Thursday, March 27th. Alliance Global Partners reaffirmed a "buy" rating on shares of Journey Medical in a research report on Thursday, May 15th.

Journey Medical Stock Up 3.2%

Shares of DERM stock traded up $0.22 during trading hours on Friday, hitting $7.14. 90,451 shares of the company's stock traded hands, compared to its average volume of 90,035. The stock has a market cap of $166.36 million, a price-to-earnings ratio of -18.31 and a beta of 0.80. Journey Medical has a 12-month low of $3.54 and a 12-month high of $8.25. The company has a quick ratio of 1.03, a current ratio of 1.34 and a debt-to-equity ratio of 1.07. The stock's fifty day simple moving average is $7.00 and its two-hundred day simple moving average is $5.88.

Journey Medical (NASDAQ:DERM - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. The business had revenue of $13.14 million for the quarter, compared to analysts' expectations of $12.05 million. Journey Medical had a negative return on equity of 52.03% and a negative net margin of 14.76%. On average, analysts expect that Journey Medical will post -1.02 EPS for the current year.

Insider Buying and Selling at Journey Medical

In other news, CEO Claude Maraoui sold 4,834 shares of the stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $6.84, for a total transaction of $33,064.56. Following the transaction, the chief executive officer directly owned 2,348,313 shares of the company's stock, valued at $16,062,460.92. This represents a 0.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 15.03% of the stock is owned by insiders.

Hedge Funds Weigh In On Journey Medical

Hedge funds and other institutional investors have recently modified their holdings of the company. Titleist Asset Management LLC lifted its holdings in shares of Journey Medical by 18.3% during the 1st quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock valued at $76,000 after buying an additional 2,000 shares during the period. Cetera Investment Advisers lifted its holdings in shares of Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after buying an additional 2,478 shares during the period. Jane Street Group LLC bought a new position in shares of Journey Medical during the 1st quarter valued at $110,000. Dimensional Fund Advisors LP bought a new position in shares of Journey Medical during the 4th quarter valued at $80,000. Finally, Kovitz Investment Group Partners LLC raised its holdings in Journey Medical by 112.9% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock worth $97,000 after purchasing an additional 13,105 shares during the period. 7.25% of the stock is owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.